In ALK-positive disease, lorlatinib seems to be superior to alectinib in terms of PFS, OS, and ORR in indirect comparative studies, but a III-phase trial of alectinib versus lorlatinib in patients with ALK-rearranged NSCLC in the I line is not available yet. Here, ALK is linked to non-small cell lung carcinoma.